Data Foundry

Drug recalls 2025

Levothyroxine Sodium Tablets — Class II drug recall D-0006-2026

Ongoing recall by ACCORD HEALTHCARE, INC., reported 2025-10-15, distributed nationwide. Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay conten

Recall numberD-0006-2026
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmACCORD HEALTHCARE, INC., Raleigh, NC, United States
Recall initiated2025-09-16
Classified2025-10-06
Reported by FDA2025-10-15
DistributedNationwide (US)
Quantity54,432 bottles
Reason classespotency, specification failure
NDC16729-0447, 16729-0447-15, 16729-0447-17, 16729-0448, 16729-0448-15, 16729-0448-17, 16729-0449, 16729-0449-15, 16729-0449-17, 16729-0450, 16729-0450-15, 16729-0450-17, 16729-0451, 16729-0451-15, 16729-0451-17, 16729-0452, 16729-0452-15, 16729-0452-17, 16729-0453, 16729-0453-15, 16729-0453-17, 16729-0454, 16729-0454-15, 16729-0454-17, 16729-0455 and 11 more
Lot numbersD2300045
Expiration dates2025-12-31

Product

Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.

Reason for recall

Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0006-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.